NeuroQuest
Immuno-based Blood Tests for Early Detection of Alzheimer's Disease
Company Overview
Snapshot
Founded in January 2008, NeuroQuest operates with 1–10 employees. The company has secured capital across two funding rounds from three investors. In May 2024, NeuroQuest received funding from the South Carolina Research Authority.
Business overview
NeuroQuest is a Health Tech & Life Sciences company focused on developing immuno-based blood tests for the early detection of Alzheimer's disease. Its core product, NeuroScreen™, is a diagnostic test based on the immune system's response to amyloid-beta accumulation. The company serves the medical diagnostics market, targeting doctors, pharma companies, clinics, laboratories, and hospitals with its biotechnology solutions for neurodegenerative diseases.
Strategic signal
In November 2022, NeuroQuest, in collaboration with AIBL, published findings on specific biomarkers for Alzheimer's disease that could lead to a blood-based screening tool. This signals significant progress in the development of non-invasive diagnostic methods for AD, potentially accelerating early detection and intervention strategies in the healthcare industry.
Log in to access full profile ›Company Intelligence Q&A
- What is NeuroQuest's primary focus?
- NeuroQuest specializes in developing immuno-based blood tests for the early detection of Alzheimer's disease, utilizing its proprietary NeuroScreen™ technology.
- When was NeuroQuest founded?
- NeuroQuest was founded in January 2008.
- Which organizations have funded NeuroQuest?
- NeuroQuest has received funding from investors including the South Carolina Research Authority and The Trendlines Group.
- What was a key development for NeuroQuest in November 2022?
- In November 2022, a collaborative study by NeuroQuest and AIBL identified specific biomarkers for Alzheimer's disease, indicating potential for a blood-based screening tool.
- What is NeuroQuest's core technology based on?
- NeuroQuest's proprietary technology is based on award-winning research by Professor Michal Schwartz of the Weizmann Institute of Science, focusing on the immune system's response to amyloid-beta accumulation.